Skye Bioscience, Inc. (NASDAQ:SKYE)
| Market Cap | $3.10M-93.3% |
| Revenue (ttm) | $0 |
| Net Income | -$37.67M+26.5% |
| EPS | -$7.59+25.9% |
| Shares Out | 4.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 283,761 |
| Open | $0.80 |
| Previous Close | $0.79 |
| Day's Range | $0.49 - $0.80 |
| 52-Week Range | $0.48 - $11.04 |
| Beta | 3.15 |
| Analysts | Buy |
| Price Target | $12.00(+1614.29%) |
| Earnings Date | Mar 9, 2027 |
About SKYE
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 9, 2027Earnings report
$SKYE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SKYE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SKYE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SKYE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SKYE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SKYE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SKYE
| VXFVanguard Extended Market ETF | $29.60K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SKYE’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-48.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
